Trials / Completed
CompletedNCT00881426
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb (Cefzil) 500 mg Cefprozil Tablets In Healthy Adults Volunteers Under Fasting Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 20 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
To demonstrate the relative bioavailability of Cefzil 500 mg Cefprozil tablets under fasting conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cefprozil 500 mg Tablets (Sandoz GmbH) | |
| DRUG | Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb) |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2004-04-01
- Completion
- 2004-04-01
- First posted
- 2009-04-15
- Last updated
- 2017-03-29
Source: ClinicalTrials.gov record NCT00881426. Inclusion in this directory is not an endorsement.